{"id":"placebo-tablet-of-dlbs1033","safety":{"commonSideEffects":[]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=placebo tablet of DLBS1033","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T04:50:28.020827+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T04:50:38.785765+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=placebo tablet of DLBS1033","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T04:50:39.679377+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3770173/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:50:40.721457+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo tablets are inert formulations designed to match the appearance and administration of an active drug while containing no therapeutic agent. They serve as the control arm in randomized controlled trials to measure the true efficacy of an investigational drug by accounting for placebo effect and natural disease progression. DLBS1033 placebo is manufactured by Dexa Medica Group for use in clinical studies of the active DLBS1033 formulation.","oneSentence":"A placebo tablet containing no active pharmaceutical ingredient, used as a control comparator in clinical trials.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:01:27.799Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T04:50:42.612679+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07121569","phase":"PHASE4","title":"Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and Outcomes","status":"COMPLETED","sponsor":"Universitas Sebelas Maret","startDate":"2024-07-06","conditions":"Ischemic Stroke, Acute","enrollment":52},{"nctId":"NCT02133521","phase":"PHASE2, PHASE3","title":"DLBS1033 for Acute Ischemic Stroke Patients","status":"TERMINATED","sponsor":"Dexa Medica Group","startDate":"2014-11-11","conditions":"Acute Ischemic Stroke, Partial Anterior Circulation Infarct, Lacunar Anterior Circulation Infarct","enrollment":80},{"nctId":"NCT02976701","phase":"PHASE2, PHASE3","title":"Effect of DLBS1033 After Primary PCI in Patients With STE-ACS","status":"TERMINATED","sponsor":"Dexa Medica Group","startDate":"2016-11","conditions":"ST Elevation Myocardial Infarction","enrollment":23},{"nctId":"NCT02145988","phase":"PHASE2, PHASE3","title":"DLBS1033 Treatment in Diabetic With Peripheral Arterial Disease","status":"TERMINATED","sponsor":"Dexa Medica Group","startDate":"2015-06-03","conditions":"Diabetes, Peripheral Arterial Disease","enrollment":11},{"nctId":"NCT01694537","phase":"PHASE2","title":"The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2012-07","conditions":"Healthy","enrollment":21},{"nctId":"NCT02362984","phase":"PHASE3","title":"DLBS1033 for the Treatment of Acute Ischemic Stroke","status":"TERMINATED","sponsor":"Dexa Medica Group","startDate":"2014-10","conditions":"Acute Ischemic Stroke","enrollment":9},{"nctId":"NCT01865474","phase":"PHASE4","title":"Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Dexa Medica Group","startDate":"2013-05","conditions":"Type 2 Diabetes Mellitus","enrollment":122},{"nctId":"NCT02146664","phase":"PHASE2, PHASE3","title":"DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization","status":"WITHDRAWN","sponsor":"Dexa Medica Group","startDate":"2015-11","conditions":"Acute Non-ST Elevation Myocardial Infarction","enrollment":""},{"nctId":"NCT01378585","phase":"NA","title":"Safety and Efficacy of DLBS1033 in Healthy Subjects","status":"COMPLETED","sponsor":"Dexa Medica Group","startDate":"2011-05","conditions":"Healthy","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL3770173"},"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["placebo tablet of Disolf"],"phase":"marketed","status":"active","brandName":"placebo tablet of DLBS1033","genericName":"placebo tablet of DLBS1033","companyName":"Dexa Medica Group","companyId":"dexa-medica-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T04:50:42.612679+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}